Milrinone is named as an intervention in 4 current clinical trials in our France, Canada, Mexico and Egypt registers. 4 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is University Hospital, Toulouse (1). The most-studied condition is Aneurysmal Subarachnoid Hemorrhage.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension
NCT04484675 · ClinicalTrials.gov ↗ · Pulmonary Hypertension Due to Left Heart Disease
|
Phase 4 | Recruiting | Zagazig University | Egypt |
|
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
NCT05267886 · ClinicalTrials.gov ↗ · Shock, Cardiogenic
|
Phase 4 | Recruiting | Ottawa Heart Institute Research Corporation | Canada |
|
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
NCT06679855 · ClinicalTrials.gov ↗ · Post-ligation Cardiac Syndrome
|
Phase 3 | Recruiting | NICHD Neonatal Research Network | Mexico |
|
Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral Ischemia
NCT04282629 · ClinicalTrials.gov ↗ · Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | Recruiting | University Hospital, Toulouse | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Milrinone on the HPRA medicines list.
No entry for Milrinone in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| University Hospital, Toulouse | 1 |
| Ottawa Heart Institute Research Corporation | 1 |
| NICHD Neonatal Research Network | 1 |
| Zagazig University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Mexico | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our France, Canada, Mexico and Egypt registers name Milrinone as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 1 with sites in France, 1 with sites in Canada, 1 with sites in Mexico and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University Hospital, Toulouse (1), Ottawa Heart Institute Research Corporation (1), NICHD Neonatal Research Network (1) and Zagazig University (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Milrinone, for example Milrinone 1 mg/ml Solution for Injection/Infusion (Pinewood Laboratories Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Milrinone has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Milrinone works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Milrinone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Milrinone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.